6 Results for "

Selpercatinib

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "Selpercatinib" in MCE Product Catalog:

13
13 Cited Publications
Cat. No.: HY-114370
CAS No.: 2152628-33-4
Purity:  99.83%
Synonyms: LOXO-292
Target:  

RET

Research Areas:  

Cancer

Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
loading...
    loading...
Cat. No.: HY-114370R
CAS No.: 2152628-33-4
Synonyms: LOXO-292 (Standard)
Target:  

Reference Standards RET

Research Areas:  

Cancer

Selpercatinib (Standard) is the analytical standard of Selpercatinib. This product is intended for research and analytical applications. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
loading...
    loading...
Cat. No.: HY-176937
CAS No.: 2234239-90-6
Target:  

RET Apoptosis

Research Areas:  

Cancer

HSN608 is an orally active, potent RET G810 mutant inhibitor. HSN608 inhibits G810C, G810R, G810D. HSN608 induces Apoptosis. HSN608 inhibits the Selpercatinib (HY-114370)-resistant RET(G810C) CDX tumors .
loading...
    loading...
Cat. No.: HY-W759629
CAS No.: 2433775-55-2
Synonyms: LOXO-292-d3
Selpercatinib-d3 (LOXO-292-d3) is deuterium labeled Selpercatinib. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
loading...
    loading...
Cat. No.: HY-114370S
Synonyms: LOXO-292-13C,d3
Selpercatinib- 13C,d3 (LOXO-292- 13C,d3) is 13C labeled Selpercatinib. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
loading...
    loading...
Cat. No.: HY-170855A
Target:  

PROTACs RET

Research Areas:  

Endocrinology Cancer

YW-N-7 TFA is a PROTAC degrader targeting RET kinase, with an IC50 of 8.4 nM. YW-N-7 TFA inhibits RET kinase activity and induces proteasome-mediated degradation of RET fusion proteins, while enhancing the anti-tumor activity of Selpercatinib (LOXO-292) (HY-114370). YW-N-7 TFA can be used in the research of cancers associated with RET gene abnormalities, including medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer .
loading...
    loading...